Ligand Pharmaceuticals Inc. (LGND) Stock Price
LGNDStock
$295.54+63.49%52W
Market Cap$5.89B
P/E47.34x
PEG Ratio1.53
Div yield—
Beta1.24
LGND Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)17.30%
Price vs S&P 500 (4W)3.21%
PEG Ratio1.53
VGM Score54.76
P/E Ratio (Annual)47.34x
LGND Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | $1.95 | $2.37 | +21.48%(+$0.42) | |
| Q1 2026 | $1.80 | $1.63 | -9.61%(-$0.17) | |
| Q4 2025 | $1.50 | $2.02 | +34.92%(+$0.52) | |
| Q3 2025 | $1.93 | $3.09 | +60.46%(+$1.16) | |
| Q2 2025 | $1.42 | $1.60 | +12.56%(+$0.18) |
LGND Analyst Recommendations
Jun 2026
Jul 2026
Aug 2026
Sep 2026
4.29
4.29
4.33
4.38
Industry Peers — Pharmaceuticals(574)
| Symbol | Value Score | Growth Score | Momentum Score | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|---|---|---|
LGNDLigand Pharmaceuticals Inc. | D | B | B | 20.3x | 54.9% | 95.4% | — | $295.54 |
| LLYEli Lilly & Co. | D | B | A | 14.9x | 49.6% | 83.4% | 27.6% | $1257.03 |
| JNJJohnson & Johnson | D | C | B | 6.2x | 7.8% | 67.7% | 14.9% | $255.56 |
| ABBVABBVIE INC. | D | C | A | 7.8x | 10.4% | 72.8% | -2.9% | $285.42 |
| MRKMerck & Co., Inc. | D | C | A | 5.4x | 4.6% | 77.3% | 21.2% | $145.95 |
| NVSNovartis AG | C | C | B | 4.9x | 3.3% | 75.0% | 15.3% | $150.62 |
| AZNAstraZeneca PLC | C | B | B | 4.3x | 8.6% | 81.3% | 21.9% | $165.41 |
| ABTAbbott Laboratories | C | C | B | 3.9x | 8.1% | 56.8% | 8.2% | $104.89 |
| NVONovo-Nordisk A/S | B | C | C | 3.5x | 5.6% | 80.7% | 20.7% | $38.83 |
| PFEPfizer Inc. | C | D | A | 2.6x | -0.2% | 74.7% | -3.5% | $29.58 |
| VRTXVertex Pharmaceuticals Inc | D | C | B | 10.1x | 10.2% | 86.0% | 8.3% | $499.74 |
About Ligand Pharmaceuticals Inc.
Ligand Pharmaceuticals is a biopharmaceutical company focused on developing and acquiring drug technologies through strategic partnerships and licensing agreements. The company generates revenue from three primary sources: royalties on commercialized products, licensing and milestone payments, and sales of its proprietary Captisol platform.